Summit Technology (BEAM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Summit Technology (BEAM)

BEAM 25.01

+5.1%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Panita who wrote (1356)	10/25/1999 11:33:00 PM
From: HerbVic	Read Replies (1) of 1386

It Could be this old news that has dampened BEAM's performance: Summit Technology, Inc. Announces Pricing of Offering WALTHAM, Mass.--(BUSINESS WIRE)--Aug. 12, 1999--Summit Technology, Inc. (NASDAQ: BEAM) today announced the public offering of 3,500,000 shares of its common stock priced at $16.00 per share. The offering is being managed by Hambrecht & Quist LLC, U.S. Bancorp Piper Jaffray and Dain Rauscher Wessels, a division of Dain Rauscher Incorporated. siliconinvestor.com Tonight I caught part of the spot on NBC News about the "future of better than perfect vision." It was VISX centric, but it should generate interest in BEAM as well. Many investors, already aware of the sector, know that BEAM has a cross licensing agreement with VISX. This is really just the beginning of the hyperbole we should see as the world wakes up to the potential of Custom Cornea(TM) combined with LADARVision(TM). Perhaps the lime light will wash out the lingering shadow left by SNRS's FDA flop and give the sector back its old energy. HerbVic

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next